Mirum Pharmaceuticals Net Worth
Mirum Pharmaceuticals Net Worth Breakdown | MIRM |
Mirum Pharmaceuticals Net Worth Analysis
Mirum Pharmaceuticals' net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Mirum Pharmaceuticals' financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Mirum Pharmaceuticals' overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Mirum Pharmaceuticals' net worth analysis. One common approach is to calculate Mirum Pharmaceuticals' market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Mirum Pharmaceuticals' stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Mirum Pharmaceuticals' net worth. This approach calculates the present value of Mirum Pharmaceuticals' future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Mirum Pharmaceuticals' cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Mirum Pharmaceuticals' net worth. This involves comparing Mirum Pharmaceuticals' financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Mirum Pharmaceuticals' net worth relative to its peers.
Enterprise Value |
|
To determine if Mirum Pharmaceuticals is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Mirum Pharmaceuticals' net worth research are outlined below:
| The company reported the previous year's revenue of 186.37 M. Net Loss for the year was (163.41 M) with profit before overhead, payroll, taxes, and interest of 64.69 M. | |
| Mirum Pharmaceuticals currently holds about 124.95 M in cash with (70.94 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.82. | |
| Mirum Pharmaceuticals has a frail financial position based on the latest SEC disclosures | |
| Over 98.0% of the company shares are owned by institutional investors | |
| Latest headline from news.google.com: Mirum Pharmaceuticals, Inc. Given Consensus Recommendation of Buy by Brokerages - MarketBeat |
Mirum Pharmaceuticals uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Mirum Pharmaceuticals. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Mirum Pharmaceuticals' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 13th of March 2024 Upcoming Quarterly Report | View | |
| 2nd of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 13th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Know Mirum Pharmaceuticals' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Mirum Pharmaceuticals is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Mirum Pharmaceuticals backward and forwards among themselves. Mirum Pharmaceuticals' institutional investor refers to the entity that pools money to purchase Mirum Pharmaceuticals' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Morgan Stanley - Brokerage Accounts | 2024-06-30 | 1.1 M | Geode Capital Management, Llc | 2024-09-30 | 936.2 K | Clearbridge Advisors, Llc | 2024-09-30 | 889.1 K | Pictet Asset Manangement Sa | 2024-06-30 | 875.1 K | Goldman Sachs Group Inc | 2024-06-30 | 759 K | Lord, Abbett & Co Llc | 2024-09-30 | 741.4 K | Polar Capital Holdings Plc | 2024-06-30 | 741 K | Avidity Partners Management Lp | 2024-09-30 | 731.1 K | First Turn Management Llc | 2024-09-30 | 647.6 K | Hhg Plc | 2024-06-30 | 5 M | Eventide Asset Management, Llc | 2024-09-30 | 3.4 M |
Follow Mirum Pharmaceuticals' market capitalization trends
The company currently falls under 'Mid-Cap' category with a current market capitalization of 2.24 B.Market Cap |
|
Project Mirum Pharmaceuticals' profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.42) | (0.44) | |
| Return On Capital Employed | (0.20) | (0.20) | |
| Return On Assets | (0.25) | (0.27) | |
| Return On Equity | (0.66) | (0.62) |
When accessing Mirum Pharmaceuticals' net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Mirum Pharmaceuticals' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Mirum Pharmaceuticals' profitability and make more informed investment decisions.
Evaluate Mirum Pharmaceuticals' management efficiency
Mirum Pharmaceuticals has return on total asset (ROA) of (0.091) % which means that it has lost $0.091 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.3984) %, meaning that it created substantial loss on money invested by shareholders. Mirum Pharmaceuticals' management efficiency ratios could be used to measure how well Mirum Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. As of the 29th of November 2024, Return On Tangible Assets is likely to drop to -0.44. In addition to that, Return On Capital Employed is likely to drop to -0.2. At this time, Mirum Pharmaceuticals' Fixed Asset Turnover is very stable compared to the past year.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 6.08 | 3.50 | |
| Tangible Book Value Per Share | (0.10) | (0.10) | |
| Enterprise Value Over EBITDA | (9.00) | (9.45) | |
| Price Book Value Ratio | 4.85 | 5.10 | |
| Enterprise Value Multiple | (9.00) | (9.45) | |
| Price Fair Value | 4.85 | 5.10 | |
| Enterprise Value | 1.1 B | 1.2 B |
The strategic initiatives led by Mirum Pharmaceuticals' management are central to its market success. By analyzing these initiatives, we provide a clear picture of the stock's growth prospects.
Enterprise Value Revenue 7.402 | Revenue 307 M | Quarterly Revenue Growth 0.894 | Revenue Per Share 6.513 | Return On Equity (0.40) |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Mirum Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Mirum Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Mirum Pharmaceuticals insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Mirum Pharmaceuticals Corporate Filings
F4 | 15th of November 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
13A | 14th of November 2024 An amended filing to the original Schedule 13G | ViewVerify |
8K | 12th of November 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
13A | 10th of July 2024 The form used by investors holding more than 5% of a company's stock, to report their beneficial ownership pursuant to Rule 13d-1 or Rule 13d-2 under the Securities Exchange Act of 1934 | ViewVerify |
Mirum Pharmaceuticals Earnings per Share Projection vs Actual
Mirum Pharmaceuticals Corporate Management
| Peter MBA | Chief Officer | Profile | |
| Eric MBA | Chief Officer | Profile | |
| Ian Clements | Chief Officer | Profile | |
| Paul Ross | Chief Officer | Profile | |
| Joanne MD | Chief Officer | Profile | |
| MSC MBA | Chief Officer | Profile |
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Mirum Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. To learn how to invest in Mirum Stock, please use our How to Invest in Mirum Pharmaceuticals guide.You can also try the Portfolio Dashboard module to portfolio dashboard that provides centralized access to all your investments.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Mirum Pharmaceuticals. If investors know Mirum will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Mirum Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.08) | Revenue Per Share 6.513 | Quarterly Revenue Growth 0.894 | Return On Assets (0.09) | Return On Equity (0.40) |
The market value of Mirum Pharmaceuticals is measured differently than its book value, which is the value of Mirum that is recorded on the company's balance sheet. Investors also form their own opinion of Mirum Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Mirum Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Mirum Pharmaceuticals' market value can be influenced by many factors that don't directly affect Mirum Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Mirum Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Mirum Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Mirum Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.